These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1524 related items for PubMed ID: 25611051

  • 1. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A, Barbui T.
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E, Cazzola M.
    Blood; 2017 Feb 09; 129(6):680-692. PubMed ID: 28028026
    [Abstract] [Full Text] [Related]

  • 11. Myeloproliferative Neoplasms: A Contemporary Review.
    Tefferi A, Pardanani A.
    JAMA Oncol; 2015 Apr 09; 1(1):97-105. PubMed ID: 26182311
    [Abstract] [Full Text] [Related]

  • 12. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM.
    Blood; 2014 Oct 16; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [Abstract] [Full Text] [Related]

  • 13. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2023 Sep 16; 98(9):1465-1487. PubMed ID: 37357958
    [Abstract] [Full Text] [Related]

  • 14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Sep 16; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 15. It is time to change thrombosis risk assessment for PV and ET?
    Passamonti F, Caramazza D, Mora B, Casalone R, Maffioli M.
    Best Pract Res Clin Haematol; 2014 Jun 16; 27(2):121-7. PubMed ID: 25189723
    [Abstract] [Full Text] [Related]

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 16; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 17. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA.
    BMC Cancer; 2019 Jun 17; 19(1):590. PubMed ID: 31208359
    [Abstract] [Full Text] [Related]

  • 18. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 17; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 19. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May 17; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 20. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J.
    Neth J Med; 1999 Feb 17; 54(2):46-62. PubMed ID: 10079679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.